Prognostic marker profile to assess risk in stage I-III hormone receptor-positive breast cancer patients

International Journal of Cancer

Volumn 124, Issue 4, 2009, Pages 896-904

  Bremer, Troy M ^a   Jacquemier, Jeceiyme ^b   Charafe Jauffret, Emmanuelle ^b,c   Viens, Patrice ^d   Birnbaum, Daniel ^b   Linke, Steven P ^a  

^a Predictive Science   (United States)

^b INSTITUT PAOLI CALMETTES   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

Author keywords

BCL2; Breast cancer; ERBB2; Hormone receptors; Muitivariate algorithm; MYC; prognosis; TP53

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MYC PROTEIN; PROSTAGLANDIN RECEPTOR; PROTEIN BCL 2; PROTEIN P53; TAMOXIFEN; TUMOR MARKER; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; HORMONE;

ADULT; AGED; ALGORITHM; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RELAPSE; CANCER SIZE; CANCER SURVIVAL; CHROMOSOME 8Q; DISEASE SEVERITY; DISTANT METASTASIS; DRUG CYTOTOXICITY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MOLECULAR RECOGNITION; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SCORING SYSTEM; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; METABOLISM; METASTASIS; METHODOLOGY; MIDDLE AGED; RISK; STATISTICAL MODEL; TREATMENT OUTCOME;

AGED; ALGORITHMS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; HORMONES; HUMANS; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASM METASTASIS; PROGNOSIS; RISK; RISK ASSESSMENT; TAMOXIFEN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 58149475691     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24001     Document Type: Article

References (31)

1. Eifel P, Axelson JA, Costa J, Crowley J, Curran WJ, Jr, Deshler A, Fulton S, Hendricks CB, Kemeny M, Kornblith AB, Louis TA, Markman M, et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer. November 1-3, 2000. J Natl Cancer Inst 2001;93:979-89.
2. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Breast Cancer Clinical Practice Guidelines in Oncology, Vol. V. 1.2007. National Comprehensive Cancer Network, 2007. http://www.nccn.org/ professionals/physician-gls/PDF/breast.pdf.
3. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Progress and promise: highlights of the international expert consensus on the primary therapv of earlv breast cancer 2007. Ann Oncol 2007; 18:1133-44.
4. Haybittle JL, Blamey RW, Elston CW, Johnson J, Doyle PJ, Campbell FC. Nicholson RI, Griffiths K. A prognostic index in primary breast cancer. Br J Cancer 1982;45:361-6.
5. Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, Parker HL. Computer program to assist in making decisions about adjuvant therapy for women with earlv breast cancer. J Clin Oncol 2001;19:980-91.
6. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
7. Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sorlie T, Dai H, He YD, van't Veer LJ, Bartelink H, van de Rijn M, Brown PO, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 2005; 102:3738-43.
8. Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, Glas AM, d'Assignies MS, Bergh J, Lidereau R, Ellis P, Harris A, Bogaerts J, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006;98:1183-92.
9. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26.
10. Ma XJ. Hilsenbeck SG. Wang W. Ding L, Sgroi DC. Bender RA. Osborne CK, Allred DC, Erlander MG. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol 2006;24:4611-19.
11. Ring BZ, Seitz RS, Beck R, Shasteen WJ, Tarr SM, Cheang MC, Yoder BJ, Budd GT, Nielsen TO, Hicks DG, Estopinal NC, Ross DT. Novel prognostic iramunohistocheraical biomarker panel for estrogen receptor-positive breast cancer. J Clin Oncol 2006:24:3039-47.
12. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005:365:671- 9.
13. Dolled-Filhart M, Ryden L, Cregger M, Jirstrom K, Harigopal M, Camp RL, Rimm DL. Classification of breast cancer using genetic algorithms and tissue microarrays. Clin Cancer Res 2006; 12:6459-68.
14. Dupuy A, Simon RM. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Tnst 2007;99:147-57.
15. Ransohoff DF. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 2004;4:309-14.
16. Simon R, Radmacher MD, Dobbin K, McShane LM. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 2003;95:14-18.
17. Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 2005;23:7350-60.
18. Debled M, MacGrogan G, de Mascarel 1, Brouste V, Bonnefoi H, Mauriac L. Expression profiling in breast carcinoma: new insights on old prognostic factors? J Clin Oncol 2007;25:4316-17; author reply 17-18.
19. Linke SP, Bremer TM, Herold CD, Sauter G, Diamond C. A multi-marker model to predict outcome in tamoxifen-treated breast cancer patients. Clin Cancer Res 2006; 12:1175-83.
20. Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, Kochli OR, Mross F, Dieterich H, Moch H, Mihatsch M, Kallioniemi OP, Sauter G. Tissue microarravs for rapid linking of molecular changes to clinical endpoints. Am J Pathol 2001; 159:2249-56.
21. Ruiz C, Seibt S, Al Kuraya K, Siraj AK, Mirlacher M, Schraml P, Maurer R, Spichtin H, Torhorst J, Popovska S, Simon R, Sauter G. Tissue microarrays for comparing molecular features with proliferation activity in breast cancer. Int J Cancer 2006; 118:2190-4.
22. Jacquemier J, Ginestier C, Rougemont J, Bardou VJ, Charafe-Jauffret E, Geneix J, Adelaide J, Koki A, Houvenaeghel G, Hassoun J, Maraninchi D, Viens P, et al. Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res 2005;65:767-79.
23. Elston CW, Ellis 10. Pathological prognostic factors in breast cancer. T. The value of histological grade in breast cancer: experience from a large studv with long-term follow-up. Histopathology 1991; 19:403-10.
24. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7.
25. Ginestier C, Charafe-Jauffret E, Bertucci F, Eisinger F, Geneix J, Bechlian D, Conte N, Adelaide J, Toiron Y, Nguyen C, Viens P, Mozziconacci MJ, et al. Distinct and complementary information provided by use of tissue and DNA microarrays in the studv of breast tumor markers. Am J Pathol 2002;161:1223-33.
26. Al-Kuraya K, Schraml P, Torhorst J, Tapia C, Zaharieva B, Novotny H, Spichtin H, Maurer R, Mirlacher M, Kochli O, Zuber M, Dieterich H, et al. Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res 2004;64:8534-40.
27. Goldhirsch A, Glick JH, Gclber RD, Coates AS, Thurlimann B, Semi HJ. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005; 16: 1569-83.
28. R Development Core Team. R, ed. 2.0.1. Vienna, Austria: R Development Core Team. 2004.
29. Paik S, Bryant J, Tan-Chiu E, Romond E, Hiller W, Park K, Brown A, Yorkers G, Anderson S, Smith R, Wickerham DL, Wolmark N. Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 2002; 94:852-4.
30. Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, Lingle WL, Flynn PJ, Ingle JN, Visscher D, Jenkins RB. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 2006;24:3032-8.
31. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MR, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98: 10869-74.